Caroline Xie
General Partner @ ICONIQ Capital
San Francisco Bay Area, United States
Caroline Xie is a Series C investor at ICONIQ Capital in San Francisco Bay Area focused on Software and Artificial Intelligence. Caroline Xie is the Board of Directors of DexCare.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Caroline Xie invests in
Stages Caroline Xie invests in
Countries Caroline Xie invests in
Investment Focus
Industry
- Software 4 (50%)
- Artificial Intelligence 4 (50%)
- Health Care 3 (38%)
- Life Science 2 (25%)
- Pharmaceutical 2 (25%)
Stage
- Series C 4 (50%)
- Series B 3 (38%)
Country
- United States 5 (63%)
- United Kingdom 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Causaly
|
Causaly develops a biomedical research discovery tool designed to find and unlock key hidden evidence in biomedicine. It amplifies human cognitive abilities to expand the boundaries of discovery toward making the best decisions in biomedicine. | $60M / Series B / Jul 13, 2023 | |
DexCare
|
DexCare is a provider of platform-as-a-service offering to manage health system capacity and demand across all lines of care. The company enables health systems to evolve their traditional, one-to-one, patient-to-provider relationships and transform them into a highly scalable digital experience for their patients— increasing revenue from new,digital-first patients while minimizing new patient acquisition costs.DexCare was founded in 2021 and is headquartered in Seattle, WA. | $75M / Series C / Jun 21, 2023 | |
Apprentice.io
|
Apprentice is The Manufacturing AI Company. Since 2014 we've built intelligent, mission-critical systems that empower teams to automate workflows they never thought possible. Our proprietary AI model, Apprentice 4.1, is specifically trained and constrained for manufacturing—ensuring strict compliance and human-in-the-loop accountability.Apprentice 4.1 can be deployed as a stand-alone AI agent, or natively embedded within our next-gen Manufacturing Suite. From our Manufacturing Execution System (MES) and Laboratory Execution System (LES) to our Connected Manufacturing Network (CMN) and Manufacturing Intelligence (Analytics), Apprentice provides a complete suite of applications to run 24/7 operations and drive significant throughput and margin improvement.Backed by $207 million in venture funding, our platform is trusted by the world's leading manufacturers—including Moderna, Catalent and Gilead—to execute over 30 million requests per month. | $65M / Series C / Mar 20, 2023 | |
|
Apprentice.io
|
Apprentice is The Manufacturing AI Company. Since 2014 we've built intelligent, mission-critical systems that empower teams to automate workflows they never thought possible. Our proprietary AI model, Apprentice 4.1, is specifically trained and constrained for manufacturing—ensuring strict compliance and human-in-the-loop accountability.Apprentice 4.1 can be deployed as a stand-alone AI agent, or natively embedded within our next-gen Manufacturing Suite. From our Manufacturing Execution System (MES) and Laboratory Execution System (LES) to our Connected Manufacturing Network (CMN) and Manufacturing Intelligence (Analytics), Apprentice provides a complete suite of applications to run 24/7 operations and drive significant throughput and margin improvement.Backed by $207 million in venture funding, our platform is trusted by the world's leading manufacturers—including Moderna, Catalent and Gilead—to execute over 30 million requests per month. | $65M / Series C / Mar 20, 2023 | |
Nayya
|
At Nayya, we believe there’s a better way to choose and use benefits. A more transparent, less confusing way for employees to control their health and financial potential. Powered by billions of data points and machine learning, our benefits experience platform delivers personalized decision support and guidance during open enrollment, new employeeonboarding, qualifying life events, and in the moments that matter all year round. This is one of the most stressful and challenging situations consumers face – and we see that as an opportunity to build an innovative response that can help millions of Americans possess the control and understanding they deserve. Join the consumers and their employers that are now living with more peace and confidence at Nayya.com. | $55M / Series C / Mar 01, 2022 | |
Notable
|
Notable is the AI platform for healthcare operations. Deployed at over 10,000 sites of care, Notable automates over a million repetitive workflows every day across Registration and Intake, Scheduling and Referrals, Assistant, Authorizations, Care Gap Closure, and HCC Chart Review. The result: personalized, streamlined care for patients, theelimination of burdensome manual work for caregivers, and improved financial health for healthcare providers. | $100M / Series B / Nov 03, 2021 | |
|
Nayya
|
At Nayya, we believe there’s a better way to choose and use benefits. A more transparent, less confusing way for employees to control their health and financial potential. Powered by billions of data points and machine learning, our benefits experience platform delivers personalized decision support and guidance during open enrollment, new employeeonboarding, qualifying life events, and in the moments that matter all year round. This is one of the most stressful and challenging situations consumers face – and we see that as an opportunity to build an innovative response that can help millions of Americans possess the control and understanding they deserve. Join the consumers and their employers that are now living with more peace and confidence at Nayya.com. | $37M / Series B / Jun 02, 2021 | |
Unite Us
|
Unite Us is a veteran-led technology company that builds coordinated care networks connecting health and social service providers together. The company helps systems and communities efficiently deliver care and services by inter-connecting providers across communities, seamlessly integrating the social determinants of health into patient care.Providers across the continuum and community are able to externally refer and track every patient’s total health journey while reporting on all tangible outcomes across a full range of services in a centralized, cohesive, and collaborative ecosystem. This social infrastructure helps communities move beyond legacy resource directories, and transform their ability to measure impact, improved health, and outcomes at scale.The company was founded in 2013 by military veterans Dan Brillman and Taylor Justice in New York, New York. | $150M / Series C / Mar 16, 2021 |
Co-Investors
About ICONIQ Capital
ICONIQ Capital is a privately-held investment firm that serves some influential families and organizations. The firm is a trusted advisor and thought partner, facilitating meaningful strategic relationships across investment opportunities, family governance, and global impact. ICONIQ provides financial advisory and family office services, andmanages direct investments across asset classes, with a specific focus on technology growth equity, venture capital, middle-market buyout, and real estate.
ICONIQ Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Caroline Xie
General Partner
|
|||
Chris Hubbell
General Partner
|
|||
Gregory Stanger
General Partner
|
|||
Kamran Zaki
Partner
|
|||
Michael Anders
Founding Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Caroline Xie invest in?
Caroline Xie invests primarily in Software, Artificial Intelligence and Health Care startups, most often at Series C and Series B stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Caroline Xie last invest?
The most recent investment recorded for Caroline Xie closed in Jul 2023. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
